Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease

Redox Report

Volumn 15, Issue 4, 2010, Pages 161-168

  Bonda, David J ^a   Mailankot, Maneesh ^b   Stone, Jeremy G ^a   Garrett, Matthew R ^a,e   Staniszewska, Magdalena ^b,f   Castellani, Rudy J ^c   Siedlak, Sandra L ^a   Zhu, Xiongwei ^a   Lee, Hyoung Gon ^a   Perry, George ^a,d   Nagaraj, Ram H ^b   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; amyloid ; hyperphosphorylated tau; indoleamine 2,3 dioxygenase; kynurenine; kynurenine pathway; quinolinic acid; tryptophan

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; AMYLOID BETA PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SENILE PLAQUE; TRYPTOPHAN METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOTTING, WESTERN; CASE-CONTROL STUDIES; HIPPOCAMPUS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; NEURONS;

EID: 77955069370     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/174329210X12650506623645     Document Type: Article

References (57)

1. Beadle GW, Mitchell HK, Nyc JF. Kynurenine as an intermediate in the formation of nicotinic acid from tryptophane by neurospora. Proc Natl Acad Sci USA 1947; 33: 155-158.
2. Takikawa O. Clinical aspects of indoleamine 2,3-dioxygenase (IDO)- initiated tryptophan metabolism: IDO is a target of drug discovery for various diseases. Int Congr Ser 2007; 1304: 290-297.
3. Wolf H. Studies on tryptophan metabolism in man. Scand J Clin Lab Invest 1974; 136 (Suppl): 1-186.
4. Dang Y, Dale WE, Brown OR. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med 2000; 28: 615-624.
5. Dang Y, Dale WE, Brown OR. Effects of oxygen on kynurenine-3- monooxygenase activity. Redox Rep 2000; 5: 81-84.
6. Dale WE, Dang Y, Brown OR. Tryptophan metabolism through the kynurenine pathway in rat brain and liver slices. Free Radic Biol Med 2000; 29: 191-198.
7. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 2001; 166: 6332-6340.
8. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-2522.
9. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989; 45: 535-541.
10. Dang Y, Xia C, Brown OR. Effects of oxygen on 3- hydroxyanthranilate oxidase of the kynurenine pathway. Free Radic Biol Med 1998; 25: 1033-1043.
11. Boehm DE, Vincent K, Brown OR. Oxygen and toxicity inhibition of amino acid biosynthesis. Nature 1976; 262: 418-420.
12. Braun JS, Sublett JE, Freyer D et al. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis'. J Clin Invest 2002; 109: 19-27.
13. Eastman CL, Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 1990; 15: 1101-1107.
14. Staniszewska MM, Nagaraj RH. 3-Hydroxykynurenine-mediated modification of human lens proteins: structure determination of a major modification using a monoclonal antibody. J Biol Chem 2005; 280: 22154-22164.
15. Amiridze N, Dang Y, Brown OR. Hydroxyl radicals detected via brain microdialysis in rats breathing air and during hyperbaric oxygen convulsions. Redox Rep 1999; 4: 165-170.
16. Dale WE, Dang Y, Amiridze N, Brown OR. Evidence that kynurenine pathway metabolites mediate hyperbaric oxygen-induced convulsions. Toxicol Lett 2000; 117: 37-43.
17. Brown OR, Lusiak-Draczynska B. Oxygen inactivation of quinolinate-producing and iron-requiring 3-hydroxyanthranilic acid oxidase: a role in hyperbaric oxygen-induced convulsions? Redox Rep 1995; 1: 383-385.
18. Klivenyi P, Toldi J, Vecsei L. Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv Exp Med Biol 2004; 541: 169-183.
19. Schwarcz R, Kohler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett 1983; 38: 85-90.
20. Schwarcz R, Foster AC, French ED, Whetsell Jr WO, Kohler C. Excitotoxic models for neurodegenerative disorders. Life Sci 1984; 35: 19-32.
21. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 1981; 72: 411-412.
22. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 2002; 7: 199-206.
23. Lim CK, Brew BJ, Guillemin GJ. Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int J Tryptophan Res 2010; 3: 1-11.
24. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotoxin Res 2005; 7: 103-123.
25. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2005; 2: 249-260.
26. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol 2001; 64: 185-218.
27. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med 2003; 41: 852-859.
28. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343-353. (Pubitemid 30162696)
29. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005; 31: 395-404.
30. Smith MA. Alzheimer disease. Int Rev Neurobiol 1998; 42: 1-54.
31. Zhu X, Lee HG, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 2007; 1772: 494-502.
32. Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol 1999; 6: 15-24.
33. Shimohama S, Tanino H, Kawakami N et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 2000; 273: 5-9.
34. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 2003; 527: 105-112.
35. Guillemin GJ, Kerr SJ, Smythe GA, Armati PJ, Brew BJ. Kynurenine pathway metabolism in human astrocytes. Adv Exp Med Biol 1999; 467: 125-131.
36. Guillemin GJ, Kerr SJ, Smythe GA et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. JNeurochem 2001; 78: 842-853.
37. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009; 4: e6344.
38. Takashima A. Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy. J Alzheimers Dis 2008; 14: 371-375.
39. Sternberger LA. Immunocytochemistry, 3rd edn. New York: Wiley, 1986.
40. Su B, Wang X, Drew KL, Perry G, Smith MA, Zhu X. Physiological regulation of tau phosphorylation during hibernation. J Neurochem 2008; 105: 2098-2108.
41. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 880-888.
42. Lee HG, Ogawa O, Zhu X et al. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol (Berl) 2004; 107: 365-371.
43. Smith MA, Zhu X, Tabaton M et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010; 19: 363-372.
44. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16: 763-774.
45. Zhu X, Su B, Wang X, Smith MA, Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 2007; 64: 2202-2210. (Pubitemid 47347959)
46. Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-767.
47. Kontush A, Berndt C, Weber W et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001; 30: 119-128.
48. Atwood CS, Moir RD, Huang X et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273: 12817-12826.
49. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-4249.
50. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653-2657.
51. Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol 1999; 6: 15-24.
52. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009; 16: 77-86.
53. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, Guillemin GJ. Effects of kynurenine pathway metabolites on intracellular NAD+ synthesis. Int J Tryptophan Res 2009; 2: 61-69.
54. Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflamm 2009; 6: 36.
55. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. JNeuroinflamm 2005; 2: 16.
56. Potter MC, Elmer GI, Bergeron R, Albuqueque EX, Guidetti P, Wu HQ. Schwarcz R. Reduction of endogenous kyrnurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010; 35: 1734-1742.
57. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathology Exp Neurol 1993; 52: 648-654.